Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product helps improve lung function and oxygenation, supporting critical care for newborns.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs lack sufficient surfactant, a substance that keeps the air sacs open. By administering Curosurf, healthcare providers aim to improve lung compliance and reduce the work of breathing, which is crucial for the infant's overall health and development.

Curosurf works by replacing the natural surfactant in the lungs, which helps to reduce surface tension and prevent the collapse of alveoli. This can lead to improved oxygenation and reduced need for mechanical ventilation in premature infants. The effects are typically observed shortly after administration.

Curosurf should be administered by trained healthcare professionals in a controlled medical setting. It is essential to follow proper handling and storage guidelines to maintain its efficacy. Always consult a healthcare provider for specific precautions and contraindications.

Curosurf is generally used in a clinical setting where interactions with other medications are carefully monitored. However, it is important to inform healthcare providers about any other treatments the infant is receiving to avoid potential complications.